Antonio Marchetti
Antonio Marchetti
Verified email at
TitleCited byYear
EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening …
A Marchetti, C Martella, L Felicioni, F Barassi, S Salvatore, A Chella, ...
Journal of clinical oncology 23 (4), 857-865, 2005
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
G D'Orazi, B Cecchinelli, T Bruno, I Manni, Y Higashimoto, S Saito, ...
Nature cell biology 4 (1), 11, 2002
Increased MET gene copy number negatively affects survival of surgically resected non–small-cell lung cancer patients
F Cappuzzo, A Marchetti, M Skokan, E Rossi, S Gajapathy, L Felicioni, ...
Journal of Clinical Oncology 27 (10), 1667, 2009
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations
A Marchetti, L Felicioni, S Malatesta, M Grazia Sciarrotta, L Guetti, ...
J Clin Oncol 29 (26), 3574-3579, 2011
IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors
FE Bleeker, S Lamba, S Leenstra, D Troost, T Hulsebos, WP Vandertop, ...
Human mutation 30 (1), 7-11, 2009
Survivin gene expression in early‐stage non‐small cell lung cancer
M Falleni, C Pellegrini, A Marchetti, B Oprandi, F Buttitta, F Barassi, ...
The Journal of Pathology: A Journal of the Pathological Society of Great …, 2003
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron, D Gandara, FR Hirsch, ...
Journal of Thoracic Oncology 5 (10), 1706-1713, 2010
Association between cigarette smoking and FHIT gene alterations in lung cancer
G Sozzi, L Sard, L De Gregorio, A Marchetti, K Musso, F Buttitta, ...
Cancer Research 57 (11), 2121-2123, 1997
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J Vansteenkiste, L Crinò, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ...
Annals of Oncology 25 (8), 1462-1474, 2014
The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies
L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ...
Nature genetics 47 (3), 250, 2015
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer
R Cazzoli, F Buttitta, M Di Nicola, S Malatesta, A Marchetti, WN Rom, ...
Journal of thoracic oncology 8 (9), 1156-1162, 2013
Assessing EGFR mutations.
A Marchetti, L Felicioni, F Buttitta
The New England journal of medicine 354 (5), 526-8; author reply 526-8, 2006
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
WEE Eberhardt, D De Ruysscher, W Weder, C Le Péchoux, P De Leyn, ...
Annals of oncology 26 (8), 1573-1588, 2015
Cooperative Signaling between α6β4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion
D Gambaletta, A Marchetti, L Benedetti, AM Mercurio, A Sacchi, R Falcioni
Journal of Biological Chemistry 275 (14), 10604-10610, 2000
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ...
Annals of Oncology 25 (9), 1681-1690, 2014
p53 inhibits α6β4 integrin survival signaling by promoting the caspase 3–dependent cleavage of AKT/PKB
RE Bachelder, MJ Ribick, A Marchetti, R Falcioni, S Soddu, KR Davis, ...
The Journal of cell biology 147 (5), 1063-1072, 1999
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia.
A Marchetti, F Buttitta, S Miyazaki, D Gallahan, GH Smith, R Callahan
Journal of virology 69 (3), 1932-1938, 1995
p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes
A Marchetti, F Buttitta, G Merlo, F Diella, S Pellegrini, S Pepe, ...
Cancer research 53 (12), 2846-2851, 1993
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study
F Buttitta, A Marchetti, A Gadducci, S Pellegrini, M Morganti, V Carnicelli, ...
British journal of cancer 75 (2), 230, 1997
Prognostic value of p21 (WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.
O Caffo, C Doglioni, S Veronese, M Bonzanini, A Marchetti, F Buttitta, ...
Clinical cancer research 2 (9), 1591-1599, 1996
The system can't perform the operation now. Try again later.
Articles 1–20